

IN THE CLAIMS:

Sub B1  
A2

-- 11. A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering 0.001 to 10 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(3-O-methyl-2-O-sulpho- $\beta$ -D-glucopyranosyl uronic acid)-(1 $\rightarrow$ 4)-O-(2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(3-O-methyl-2-O-sulpho- $\alpha$ -L-idopyranosyl uronic acid)-(1 $\rightarrow$ 4)-2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranoside or a salt thereof per kg body weight of the patient. --

-- 12. A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering 0.30 to 30 mg of methyl O-(3,4-di-O-methyl-2,6-di-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(3-O-methyl-2-O-sulpho- $\beta$ -D-glucopyranosyl uronic acid)-(1 $\rightarrow$ 4)-O-(2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(3-O-methyl-2-O-sulpho- $\alpha$ -L-idopyranosyl uronic acid)-(1 $\rightarrow$ 4)-2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranoside or a salt thereof. --

Sub 7  
-- 13. The method of claim 11, comprising administering a dodecasodium salt thereof. --

-- 14. The method of claim 12, comprising administering a dodecasodium salt thereof. --

Sub A  
-- 15. A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering 0.001 to 10 mg of methyl O-(2,3,4-tri-O-methyl-6-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(2,3-di-O-methyl- $\beta$ -D-glucopyranosyl uronic acid)-(1 $\rightarrow$ 4)-O-(2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(2,3-di-O-methyl- $\alpha$ -L-idopyranosyl uronic acid)-(1 $\rightarrow$ 4)-2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranoside or a salt thereof per kg body weight of the patient. --

Sub B  
-- 16. A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering 0.30 to 30 mg of a methyl O-(2,3,4-tri-O-methyl-6-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(2,3-di-O-methyl- $\beta$ -D-glucopyranosyl uronic acid)-(1 $\rightarrow$ 4)-O-(2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranosyl)-(1 $\rightarrow$ 4)-O-(2,3-di-O-methyl- $\alpha$ -L-idopyranosyl uronic acid)-(1 $\rightarrow$ 4)-2,3,6-tri-O-sulpho- $\alpha$ -D-glucopyranoside or a salt thereof. --

Sub  
El

A2 non

[illegible]